Neşe Nalan, Kumbaraci Banu S, Baydar Dilek E, Kiliçaslan Işin, Sari Ayşegül A, Şen Sait, Gönül Ipek I, Kankaya Duygu, Özlük Yasemin, Ermete Murat, Özağari Ayşim, Bal Nebil, Kiremitçi Saba, Yildiz Kürşat, Tuna Burçin, Şen Nilay, Yörükoğlu Kutsal
*Department of Pathology, Medical Faculty, Celal Bayar University, Manisa †Department of Pathology, Medical Faculty, Agean University ∥Department of Pathology, Katip Çelebi University, Izmir Atatürk Training and Research Hospital §§Department of Pathology, Medical Faculty, Dokuz Eylül University, Izmir ‡Department of Pathology, Medical Faculty, Hacettepe University ¶Department of Pathology, Medical Faculty, Gazi University #Department of Pathology, Medical Faculty, Ankara University, Ankara §Department of Pathology, Istanbul Faculty of Medicine, Istanbul University **Department of Pathology, Şişli Etfal Hospital, Istanbul ††Department of Pathology, Medical Faculty, Başkent University, Adana ‡‡Department of Pathology, Medical Faculty, Kocaeli University, Kocaeli ∥∥Department of Pathology, Medical Faculty, Pamukkale University, Denizli, Turkey.
Appl Immunohistochem Mol Morphol. 2016 Apr;24(4):253-60. doi: 10.1097/PAI.0000000000000188.
Small cell carcinoma (SmCC) is a rare and aggressive neuroendocrine carcinoma of the bladder. Neuroendocrine carcinomas expressing somatostatin receptors (SSTR) in other viscera such as lung, pancreas, and gastrointestinal system respond to therapy with somatostatin analogs. In the present study, expressions of SSTRs 1 to 5 including type 2A are investigated by immunohistochemistry (IHC) and their relationship with clinicopathologic factors was evaluated. Hundred primary bladder SmCC cases were collected from 12 centers in Turkey. Forty-three cases were pure SmCC. Other cases had mostly papillary urothelial carcinoma as a second component. The percentage of the SmCC component ranged from 5% to 100%. SSTR-2A expression was membranous, whereas the other receptors showed cytoplasmic staining. The percentages of positive cases for SSTR-1, SSTR-2A, SSTR-3, SSTR-4, and SSTR-5 were 4% (3/75), 61.4% (54/88), 2.4% (2/84), 24.4% (20/82), and 6.25% (5/80), respectively. The percentage of SmCC component was positively correlated with the percentage of SSTR-2A expression (P=0.003) while negatively correlated with patient age (P=0.032). SSTR-2A expression was correlated with survival as a bad prognostic factor (P=0.018). SSTR-1, SSTR-3, SSTR-4, and SSTR-5 expressions did not show any statistical significance with any parameter. In conclusion, although the limited number of cases with adequate term follow-up, SSTR-2A expression could be a prognostic factor and somatostatin analogs therapeutic candidate for SmCCs of the bladder as these tumors show high percentage of SSTR-2A expression.
小细胞癌（SmCC）是一种罕见的侵袭性膀胱神经内分泌癌。在肺、胰腺和胃肠道系统等其他内脏中表达生长抑素受体（SSTR）的神经内分泌癌对生长抑素类似物治疗有反应。在本研究中，通过免疫组织化学（IHC）研究了包括2A型在内的SSTRs 1至5的表达，并评估了它们与临床病理因素的关系。从土耳其的12个中心收集了100例原发性膀胱SmCC病例。43例为纯SmCC。其他病例大多以乳头状尿路上皮癌作为第二成分。SmCC成分的百分比范围为5%至100%。SSTR-2A表达为膜性，而其他受体显示胞质染色。SSTR-1、SSTR-2A、SSTR-3、SSTR-4和SSTR-5阳性病例的百分比分别为4%（3/75）、61.4%（54/88）、2.4%（2/84）、24.4%（20/82）和6.25%（5/80）。SmCC成分的百分比与SSTR-2A表达的百分比呈正相关（P = 0.003），而与患者年龄呈负相关（P = 0.032）。SSTR-2A表达作为不良预后因素与生存率相关（P = 0.018）。SSTR-1、SSTR-3、SSTR-4和SSTR-5表达与任何参数均无统计学意义。总之，尽管随访期足够的病例数量有限，但SSTR-2A表达可能是膀胱SmCC的一个预后因素和生长抑素类似物治疗的候选指标，因为这些肿瘤显示出较高百分比的SSTR-2A表达。
